HepaTx is pioneering innovative cell therapies aimed at treating late-stage liver disease through regenerative medicine technologies. The company focuses on developing treatments that utilize stem cells to restore liver function, presenting a viable alternative to traditional liver transplants. With over 30 million Americans affected by liver disease, and a significant number facing end-stage liver failure, HepaTx aims to address the critical shortage of available organs for transplant. Their approach involves the administration of hepatocyte-like cells designed to replace damaged liver cells, potentially revitalizing the organ's functionality and offering a solution to the dire need for effective therapies in this field.

The proprietary technology developed by HepaTx, which is licensed from Stanford University, emphasizes the scalability and practicality of their manufacturing process. This allows for the production and distribution of allogenic cells that can be banked and administered to patients in need. Recent studies have shown that their lead product, Hx-001, exhibits characteristics of hepatocyte lineage and possesses immunomodulatory properties, which may enhance its therapeutic efficacy. By fine-tuning cell functions, HepaTx aims to tackle a range of liver-related diseases, including hepatitis, cirrhosis, and metabolic disorders, thereby transforming the landscape of liver care and providing hope to thousands awaiting life-saving interventions.

United States

Our vision is to provide regenerative medicine treatments that free patients from chronic liver disease and help usher in an era where diseased and damaged tissues can be repaired.

HepaTx

Company Details